Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Carcinoma, Non-Small-Cell Lung 7Colorectal Neoplasms 6Biliary Tract Neoplasms 5Sarcoma 3Rectal Neoplasms 3Colonic Neoplasms 3Advanced or Metastatic Solid Tumors 3Uterine Cervical Neoplasms 2Solid Tumors 2Nasopharyngeal Carcinoma 2Gastrointestinal Stromal Tumors 2Carcinoma, Ovarian Epithelial 2Carcinoma, Hepatocellular 2Thymoma 1Stomach Neoplasms 1Squamous Non-small Cell Lung Cancer 1Solid Tumor 1Small Cell Lung Carcinoma 1Rare Tumour 1Prostatic Neoplasms 1Piebaldism 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasms, Multiple Primary 1Neoplasm Metastasis 1NSCLC 1Meningeal Carcinomatosis 1Lung Neoplasms 1Locally Advanced Rectal Carcinoma 1Histiocytoma, Malignant Fibrous 1

Interventions

Cisplatin 127Gemcitabine 71Radiotherapy, Intensity-Modulated 61toripalimab 39Capecitabine 37Docetaxel 36Fluorouracil 35Radiotherapy 24camrelizumab 23Drug Therapy 22nimotuzumab 18spartalizumab 13pembrolizumab 13nedaplatin 12Chemoradiotherapy 12sintilimab 11apatinib 11Induction Chemotherapy 11Immune Checkpoint Inhibitors 11tislelizumab 10Nivolumab 10Magnetic Resonance Spectroscopy 10Specimen Handling 9Radiation 9Cetuximab 9Carboplatin 9endostar protein 8Paclitaxel 8Bevacizumab 8anlotinib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Nasopharyngeal Carcinoma × envafolimab × Clear all
NCT06059261 2026-02-18

Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.

Chongqing University Cancer Hospital

Phase 2 Recruiting
30 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT06055816 2023-09-28

Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma

Zhejiang Cancer Hospital

Phase 2 Recruiting
40 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡